MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

NCT05604287 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2024-07-11

No results posted yet for this study

Summary

This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.

Conditions

  • Healthy Participants

Interventions

DRUG

ID119031166M

The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.

DRUG

Placebo

The participant will receive a oral dose of Placebo.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • YUNOVIA CO.,LTD.

    collaborator UNKNOWN

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2024-04-12
Completion
2024-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05604287 on ClinicalTrials.gov